These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 24460691)
1. Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications. Burford NT; Traynor JR; Alt A Br J Pharmacol; 2015 Jan; 172(2):277-86. PubMed ID: 24460691 [TBL] [Abstract][Full Text] [Related]
2. Allostery at opioid receptors: modulation with small molecule ligands. Livingston KE; Traynor JR Br J Pharmacol; 2018 Jul; 175(14):2846-2856. PubMed ID: 28419415 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505. Dietis N; Niwa H; Tose R; McDonald J; Ruggieri V; Filaferro M; Vitale G; Micheli L; Ghelardini C; Salvadori S; Calo G; Guerrini R; Rowbotham DJ; Lambert DG Br J Pharmacol; 2018 Jul; 175(14):2881-2896. PubMed ID: 29524334 [TBL] [Abstract][Full Text] [Related]
4. Strategies towards safer opioid analgesics-A review of old and upcoming targets. Varga BR; Streicher JM; Majumdar S Br J Pharmacol; 2023 Apr; 180(7):975-993. PubMed ID: 34826881 [TBL] [Abstract][Full Text] [Related]
5. A promising chemical series of positive allosteric modulators of the μ-opioid receptor that enhance the antinociceptive efficacy of opioids but not their adverse effects. Pryce KD; Kang HJ; Sakloth F; Liu Y; Khan S; Toth K; Kapoor A; Nicolais A; Che T; Qin L; Bertherat F; Kaniskan HÜ; Jin J; Cameron MD; Roth BL; Zachariou V; Filizola M Neuropharmacology; 2021 Sep; 195():108673. PubMed ID: 34153316 [TBL] [Abstract][Full Text] [Related]
6. IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders. Pagare PP; Flammia R; Zhang Y Pharmacol Res; 2024 Jan; 199():107023. PubMed ID: 38081336 [TBL] [Abstract][Full Text] [Related]
8. Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators. Wang H; Cao D; Gillespie JC; Mendez RE; Selley DE; Liu-Chen LY; Zhang Y Future Med Chem; 2021 Mar; 13(6):551-573. PubMed ID: 33590767 [TBL] [Abstract][Full Text] [Related]
9. Historical perspectives and recent advances in small molecule ligands of selective/biased/multi-targeted μ/δ/κ opioid receptor (2019-2022). He Y; Su Q; Zhao L; Zhang L; Yu L; Shi J Bioorg Chem; 2023 Dec; 141():106869. PubMed ID: 37797454 [TBL] [Abstract][Full Text] [Related]
10. IUPHAR themed review: Opioid efficacy, bias, and selectivity. Ramos-Gonzalez N; Paul B; Majumdar S Pharmacol Res; 2023 Nov; 197():106961. PubMed ID: 37844653 [TBL] [Abstract][Full Text] [Related]
11. Alternative pain management via endocannabinoids in the time of the opioid epidemic: Peripheral neuromodulation and pharmacological interventions. Lee MT; Mackie K; Chiou LC Br J Pharmacol; 2023 Apr; 180(7):894-909. PubMed ID: 34877650 [TBL] [Abstract][Full Text] [Related]
12. Structural and dynamic insights into the activation of the μ-opioid receptor by an allosteric modulator. Kaneko S; Imai S; Uchikubo-Kamo T; Hisano T; Asao N; Shirouzu M; Shimada I Nat Commun; 2024 May; 15(1):3544. PubMed ID: 38740791 [TBL] [Abstract][Full Text] [Related]